To highlight the disparities in hepatitis C treatment rates among different insurance types, particularly focusing on the impact of prior authorization on treatment access.
Key Findings:
Only 26.5% of people with hepatitis C were treated in an urban academic center, highlighting a critical gap in care.
Treatment rates varied significantly by insurance type: Medicare (55%), private commercial (48%), Medicaid (32%), and no insurance (21%), indicating systemic inequities.
Homelessness and substance use disorder are significant predictors of low treatment rates, underscoring the need for targeted interventions.
Prior authorization remains a major barrier to treatment initiation across various insurance types, necessitating policy reform.
Interpretation:
Removing prior authorization for Medicaid has not fully addressed the treatment disparities, especially for those with public insurance and other barriers like homelessness and substance use disorders, indicating a need for comprehensive policy changes.
Limitations:
The study primarily focuses on urban settings, which may not represent rural areas and their unique challenges.
Findings may not generalize to all states or insurance plans due to varying policies, and potential biases in urban studies could affect the results.
Conclusion:
To achieve equitable hepatitis C elimination, prior authorization barriers must be removed across all insurance types, as untreated cases lead to ongoing transmission and increased healthcare costs, emphasizing the urgency of this issue.
